<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39326023</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1175-8716</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><Issue>1603</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>The New Zealand medical journal</Title><ISOAbbreviation>N Z Med J</ISOAbbreviation></Journal><ArticleTitle>Intravitreal therapy in neovascular age-related macular degeneration-adapting to increasing demand and changing times.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>137</EndPage><MedlinePgn>129-137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.26635/6965.6597</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To report the outcomes of patients with neovascular age-related macular degeneration (nAMD) at Palmerston North Eye Clinic (PNEC) during 2020 and 2021, comparing time to treatment initiation based on nurse-injector availability and during COVID-19 restrictions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were recorded from a prospective database for patients with nAMD at PNEC. Each patient's electronic health record was reviewed to ensure the accuracy of the database and to fill in missing data points. Statistics were done using Microsoft Excel and R.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and fifty-six eyes were diagnosed with nAMD during the study. Mean time from referral triage to first injection was 13.08 days across the study period. Time to treatment initiation was not statistically different by level of COVID-19 restriction but there was a significant difference in first specialist appointment to injection interval when three nurse-injectors were available compared to four. The effect seemed most evident in subsequent months after reduced nurse-injector availability began.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite an increase in nAMD diagnoses each year, PNEC continues to meet national guidelines for interval from referral to treatment initiation through innovations in practice. As demand for intravitreal injections continues to increase, further resourcing and research into newer agents will be required to keep wait times compliant with guidelines.</AbstractText><CopyrightInformation>Â© PMA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nunns</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>House Officer, Palmerston North Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Vidit</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Training Ophthalmology Registrar, Waikato.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ah-Chan</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Consultant Ophthalmologist, Palmerston North Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>N Z Med J</MedlineTA><NlmUniqueID>0401067</NlmUniqueID><ISSNLinking>0028-8446</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZL1R02VT79</RegistryNumber><NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="Y">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="Y">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N" Type="Geographic">New Zealand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057135" MajorTopicYN="N">Wet Macular Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Nil.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>16</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326023</ArticleId><ArticleId IdType="doi">10.26635/6965.6597</ArticleId></ArticleIdList></PubmedData></PubmedArticle>